Oxidative/nitrative modifications of plasma proteins and thiols from patients with schizophrenia

Neuropsychobiology

Volumn 59, Issue 1, 2009, Pages 1-7

  Dietrich Muszalska, Anna ^a   Olas, Beata ^b   Głowacki, Rafal ^b   Bald, Edward ^b  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b UNIVERSITY OF LODZ   (Poland)

Author keywords

3 Nitrotyrosine; Carbonyl group; Homocysteine; Oxidative nitrative stress; Schizophrenic disorders; Thiols

Indexed keywords

3 NITROTYROSINE; BIOLOGICAL MARKER; CARBONYL DERIVATIVE; CLOZAPINE; CYSTEINE; CYSTEINYLGLYCINE; GLUTATHIONE; HOMOCYSTEINE; OLANZAPINE; PLASMA PROTEIN; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; RISPERIDONE; THIOL;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; NITRATIVE STRESS; OXIDATIVE STRESS; PARANOID SCHIZOPHRENIA; POLAND; PRIORITY JOURNAL;

ADULT; BIOLOGICAL MARKERS; BLOOD PROTEINS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYSTEINE; DIPEPTIDES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUTATHIONE; HOMOCYSTEINE; HUMANS; MALE; OXIDATIVE STRESS; SCHIZOPHRENIA; TYROSINE;

EID: 60049087756     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000202822     Document Type: Article

References (41)

1. Reddy RD, Yao JK: Free radical pathology in schizophrenia: a review. Prostaglandins Leukot Essent Fatty Acids 1996;55:33-34.
2. Yao JK, Reddy R, McElhinny LG, van Kam-men DP: Reduced status of plasma total antioxidant capacity in schizophrenia. Schizophr Res 1998;32:1-8.
3. Dietrich-Muszalska A, Olas B, Rabe-Jablonska J: Oxidative stress in blood platelets from schizophrenic patients. Platelets 2005;16: 386-391.
4. Li HC, Chen QZ, Ma Y, Zhou JF: Imbalanced free radicals and antioxidant defense systems in schizophrenia: a comparative study. J Zhejian Univ Sci B 2006;12:981-986.
5. Dietrich-Muszalska A, Olas B: Isoprostanes as indicators of oxidative stress in schizophrenia. World J Biol Psychiatry 2007;14: 1-6.
6. Dietrich-Muszalska A, Kontek B: Lipid peroxidation in patients with schizophrenia. Current Topics in Biophysics. XIII Conference of Polish Biophysics Society, Lodz, 2007, B-28.
7. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, American Psychiatric Press, 1994.
8. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC: The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59:22-33.
9. Khan J, Brennan DM, Bradley N, Gao B, Brukdorfer R, Jacobs M: 3-Nitrotyrosine in the proteins of human plasma determined by an ELISA method. Biochem J 1998;330:795-801.
10. Olas B, Nowak P, Kolodziejczyk J, Ponczek M, Wachowicz B: Protective effects of resveratrol against oxidative/nitrative modifications of plasma proteins and lipids exposed to peroxynitrite. J Nutr Biochem 2006; 17:96-102.
11. Buss H, Chan TP, Sluis KB, Domigan NM, Winterbourn CC: Protein carbonyl measurement by a sensitive ELISA method. Free Radic Biol Med 1997;23:361-366.
12. Levine RL, Garland D, Oliver CN, Amici A, Climent I, Lenz AG, Ahn BW, Shaltiel S, Stadtman ER: Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol 1990;186:464-478.
13. Glowacki R, Wójcik K, Bald E: Facile and sensitive method for the determination of mesna in plasma by high-performance liquid chromatography with ultraviolet detection. J Chromatogr 2001;914:29-35.
14. Bald E, Chwatko G, Glowacki R, Kusmierek K: Analysis of plasma thiols by high-performance liquid chromatography with ultraviolet detection. J Chromatogr 2004;1032:109-115.
15. Dietrich-Muszalska A: Evaluation of the effects of different concentrations of risperidone, corresponding to the drug doses used in treatment of schizophrenic patients, on lipid peroxidation in plasma and blood platelets at in vitro studies. Psychiatr Psychol Klin 2004;4:215-223.
16. Dietrich-Muszalska A, Rabe-Jablonska J, Zgirski A: The effects of olanzapine (Zolafren) on lipid peroxidation in human blood platelets and plasma: in vitro studies. Psychiatr Psychol Klin 2004;4:13-19.
17. Dietrich-Muszalska A: The impact of different concentrations of clozapine on changes of lipid peroxidation in human plasma - in vitro studies. Psychiatr Psychol Klin 2005;1: 18-25.
18. Young J, McKinney SB, Ross BM, Wahle KW, Boyle SP: Biomarkers of oxidative stress in schizophrenic and control subjects. Prostaglandins Leukot Essent Fatty Acids 2007;76: 73-85.
19. Yilmaz N, Herken H, Cicek HK, Celik A, Yureklin M, Akyol O: Increased levels of nitric oxide, cortisol and adrenomedullin in patients with chronic schizophrenia. Med Princ Pract 2007;6:137-141.
20. Taneli F, Pirildar S, Akdeniz F, Uyanik BS, Ari Z: Serum nitric oxide metabolite levels and the effect of antipsychotic therapy in schizophrenia. Arch Med Res 2004;35:401-405.
21. Bartosz G: Peroxynitrite: mediator of the toxic action of nitric oxide. Acta Biochim Pol 1996;43:645-659.
22. Soszynski M, Bartosz G: Effect of peroxynitrite on erythrocytes. Biochim Biophys Acta 1996;1291:107-114.
23. Ischiropoulos H, Al-Mehdi AB: Peroxynitrite-mediated oxidative protein modifications. FEBS Lett 1995;364:279-282.
24. Mondoro TH, Shafer BC, Vostal JG: Peroxynitrite-induced tyrosine nitration and phosphorylation in human platelets. Free Radic Biol Med 1987;22:1055-1063.
25. Ducrocq C, Blanchard B, Pignatelli B, Oshima H: Peroxynitrite: an endogenous oxidizing and nitrating agent. Cell Mol Life Sci 1999;55:1068-1077.
26. Zoroglu SS, Herken H, Yurekli M, Uz E, Tutkun H, Savas HA, Bagci C, Ozen ME, Cengiz B, Cakmak EA, Dogru MI, Akyol O: The possible pathophysiological role of plasma nitric oxide and adrenomedullin in schizophrenia. J Psychiatr Res 2002;36:309-315.
27. Srivastava N, Barthwal MK, Dalal PK, Agarwal AK, Nag D, Srimal RC, Seth PK, Dikshit M: Nitrite content and antioxidant enzymes levels in the blood of schizophrenic patients. Psychopharmacology 2001;158:140-145.
28. Berstein HG, Bogerts B, Keilhoff G: The many faces of nitric oxide in schizophrenia. A review. Schizophr Res 2005;78:69-86.
29. Haidemenos A, Kontis D, Kallai E, Allin M, Lucia B: Plasma homocysteine, folate and B12 in chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2007;15: 1289-1296.
30. Bleich S, Junemann A, von Ahsen N, Lausen B, Ritter K, Beck G, Naumann GO, Kamhuber J: Homocysteine and risk of open-angle glaucoma. J Neural Transm 2002;109:1499-1504.
31. Sachdev PS, Valenzuela M, Wang XL, Looi JC, Brodaty H: Relationship between plasma homocysteine levels and brain atrophy in healthy elderly individuals. Neurology 2002; 58:1539-1541.
32. Brown AS, Bottiglieri T, Schaefer CA, Quesenberry CP Jr, Liu L, Bresnahan M, Susser ES: Elevated prenatal homocysteine levels as a risk factor for schizophrenia. Arch Gen Psychiatry 2007;64:980-981.
33. Song H, Ueno S, Numata S, Iga J, Shibuya-Tayoshi S, Nakataki M, Tayoshi S, Yamauchi K, Sumitani S, Tomotake T, Tada T, Tanahashi T, Itakura M, Ohmori T: Association between PNPO and schizophrenia in the Japanese population. Schizophr Res 2007;97: 264-270.
34. Lipton SA, Kim W, Coi Y, Kumar S, D'Emilia DM, Rayadu PV, Arnelle DR, Stamler JS: Neurotoxicity associated with dual actions of homocysteine at the N-methyl- D -aspartate receptor. Proc Natl Acad Sci USA 1997; 94:5923-5928.
35. Ho PI, Ortiz D, Rogers E, Shea TM: Multiple aspects of homocysteine neurotoxicity: glutamate excitotoxicity, kinase hyperactivation and DNA damage. J Neurosci Res 2002; 70:694-702.
36. Moore P, El-Sherbeny A, Roon P, Schoenlein PV, Ganapathy V, Smoth SB: Apoptotic cell death in the mouse retinal ganglion cell layer is induced in vivo by the excitatory amino acid homocysteine. Exp Eye Res 2001;73:45-57.
37. Dimitrova KR, Degroot KW, Suyderhoud JP, Pirovic EA, Munro TJ, Wieneke J, Myers AK, Kim YD: 17- β estradiol preserves endothelial cell viability in an in vitro model of homocysteine-induced oxidative stress. J Cardiovasc Pharmacol 2002;39:347-353.
38. Yao JK, Reddy R, McElhinny LG, van Kammen DP: Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications. CNS Drugs 2001;15: 287-310.
39. Do HQ, Trabesinger AH, Kirsten-Kruger M, Lauer CJ, Dydak U, Hell D, Holsboer F, Boesiger P, Cuenod M: Schizophrenia: glutathione deficit in cerebrospind fluid and prefrontal cortex in vivo. Eur J Neurosci 2000; 12:3721-3728.
40. Yao JK, Leonard S, Reddy R: Altered glutathione redox state in schizophrenia. Dis Markers 2006;22:83-93.
41. Castagné V, Rougemont M, Cuenod M, Do KQ: Low brain glutathione and ascorbic acid associated with dopamine uptake inhibition during rat's development induce long-term cognitive deficit: relevance to schizophrenia. Neurobiol Dis 2004;15:93-105.